Summary:
Aptitude Medical Systems has received FDA emergency use authorization for its Metrix COVID/Flu multiplex test, a next-generation molecular diagnostic that provides lab-quality results in 20 minutes for at-home and point-of-care use.
Key Takeaways:
- Rapid, Accessible Testing – The Metrix test delivers molecular-level accuracy in just 20 minutes, making it suitable for both home and clinical use.
- Cost-Effective Alternative – It reduces the financial burden of molecular diagnostics, offering a viable replacement for traditional tests.
- Nationwide Availability – Distributed through Aptitude and partners, it enhances urgent care efficiency and expands access to reliable respiratory virus detection.
Aptitude Medical Systems, Inc. has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its next-gen molecular Metrix COVID/Flu multiplex test. This innovative test represents a major advancement in accessible molecular diagnostics.
“Molecular diagnostics are the gold standard for accuracy, but traditional systems are expensive, slow, and force molecular to be greatly underutilized. Metrix changes all that,” says Scott Ferguson PhD, CEO of Aptitude. “We built Metrix to dramatically expand the reach of molecular diagnostics by breaking cost and accessibility barriers. Our Metrix COVID/Flu test empowers individuals to get their own lab-quality results on the spot in their homes and enables healthcare providers to upgrade from existing molecular and antigen testing platforms while lowering total cost of care.”
Metrix COVID/Flu Multiplex Test Can Be Utilized in Any Environment
The Metrix COVID/Flu multiplex test simultaneously detects and differentiates SARS-CoV-2, Influenza A virus, and Influenza B virus in 20 minutes. Authorized for over-the-counter (OTC) use, it can be utilized in any environment, including at home and in CLIA-waived point-of-care (POC) settings.
“COVID-19 and flu are the top respiratory health threats in the United States, driving tens of millions of urgent care visits annually,” says Jackson Gong PhD, COO, “Healthcare providers often find traditional molecular testing too cumbersome and cost prohibitive, and instead resort to antigen tests which offer much lower clinical value. What makes Metrix so exciting for urgent care is that it truly solves the cost burden, allowing providers to deliver better medicine and improve the financial viability of their practices, on which over half of Americans depend. The Metrix COVID/Flu test is available nationwide through Aptitude and our distribution partners in collaboration with Sekisui Diagnostics.”
Aptitude is a deep-tech healthcare company revolutionizing infectious disease detection and treatment. Its mission is to democratize diagnostics by providing actionable lab-quality results, anywhere, in minutes. The Metrix COVID/Flu multiplex test is the second FDA-authorized molecular test on the platform. Aptitude has an extensive development pipeline to deliver on this mission for a wide range of health and wellness conditions.
This work is funded in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority, under contract number 75A50123C00013.
Featured Image: The FDA-authorized Metrix COVID/Flu molecular test detects and differentiates COVID, Flu A, and B in 20 minutes. It may be used in home and CLIA-waived settings. Image: Aptitude Medical Systems
